The quest for better analgesics for the treatment of peripheral neuropathic pain: navigating the sodium channels

Keppel Hesselink JM1,2*

1 Department of health, University of Witten/Herdecke, Germany
2 Institute for Neuropathic Pain, Bosch en Duin, the Netherlands

Introduction

To treat peripheral neuropathic pain by prescribing systemic acting drugs such as amitriptyline, duloxetine and gabapentinoids is actually quite old fashioned; none of these drugs are targeted to the exact pathogenesis of the problem, and thus the entire system is flooded with these compounds after oral intake. This is the main reason for the wide array of adverse events induced by these drugs and the low patient compliance. Especially in frail elderly patients, which are also prone to drug-drug interactions, more targeted therapies are welcomed. Clearly the search for innovative and new peripheral acting analgesics is driven by this goal. This commentary serves to take the discussion one step further. To the field of peripheral acting analgesics in topical formulations.

Sodium channels and the pathogenesis of peripheral painful neuropathy

Increasingly sodium channels are recognized as the pathogenetic base of many peripheral painful neuropathies. For instance, Painful Diabetic Neuropathy (PDN) can already manifest itself very early during the course of diabetes, even in patients with only slight signs of impaired glucose tolerance. Some patients with chronic diabetes however, never suffer from DPN [1]. DPN might therefore not solely be a complication of diabetes but could also be based on mutations at certain sodium channels, these mutations have now been identified both in nerve cells as well as in pancreatic beta cells. It is even suggested that these mutations increase independently the risk for diabetes and the risk for painful DPN [1]. Especially the sodium channels Nav1.7, 1.8, and 1.9 are key for activating the pain-mediating nociceptors [2]. Disturbances in the structure or function of these channels can lead to painful small-fiber neuropathy (SFN), a pathological state frequently found in PDN, chronic idiopathic axonal neuropathy (CIAP) and a number of internal disorders, such as sarcoidosis.

Some years ago, new findings of a gain-of-function mutation on the Nav 1.8 and Nav 1.9 channel provoked some scientist to claim Nav 1.8 or Nav 1.9 blockers were an interesting new inroad for treating peripheral neuropathic pain syndromes. After the first wave of presumed selective Nav 1.7 blockers, such as CNV1014802 (also known as BIIB074, vixotrigine, raxatrigine), new selective blockers are now under development, such as the Nav 1.8 blockers from Vertex, VX-150 and VX-128. The selectivity of these blockers however, remains to be seen, as in the past selective Nav 1.7 blockers sometimes appeared to be less selective than was initially indicated by the inventors [3]. This wave of new Nav blockers and the importance of the sodium channels for the pathogenesis of chronic pain syndromes, even in fibromyalgia, provoked some authors to speak about ‘nav-igating pain’ [4].

Nav-igating of peripheral neuropathic pain: the quest for topical sodium channel blockers

The oldest known sodium channel blocker used in medicine for its analgesic and anesthetic properties is cocaine. [5]. By using topical cocaine solutions, influenced by the work of the young Dr. Sigmund Freud, physicians were inducing local analgesic and anesthetic effects. The ophthalmologist Carl Koller discovered this topical analgesic effect of cocaine in 1884 [6]. We can therefore state that nav-igating the sodium channel to obtain clinical relevant effects of nociceptor inhibition is one of the oldest pharmacological pain-reducing techniques. Interestingly, this application of cocaine was topical. Sadly enough, due to the excellent absorption of cocaine via the cornea, dependency and abuse limited its use. Systemic side effects after topical application of course needed and needs to be avoided. One of the quests of our time therefore is therefore to find non-skin penetrating sodium channel blockers, which can reach the epidermal targets in peripheral neuropathic pain syndromes (the nociceptors, small fibers, but also cross-talking cells such as keratinocytes and immune-competent cells).

In the epidermis, the small nerve fibers and their nociceptors express a number of subtypes of sodium channels, but we still are in the explorative phase about the exact function of all these channels. Nine subtypes of sodium channel have been identified on mammalian cells, and most, apart from the Nav1.2 channel, expressed in the central nervous system, and Nav1.4 and Nav1.5 channels, expressed in muscle, play possibly an important role in the genesis of peripheral neuropathic pain, as these other channels are expressed in the dorsal root ganglion neurons (DRGs) and the nociceptors in the skin. Phenytinon is a non-selective (broad-acting) sodium channel blocker, because its binding-site is situated at the inner cytoplasmatic membrane, at the inner vestibule of the pore. This binding site is present in all members of sodium channel family [7]. A new insight makes this channel blocker even more interesting, after being in the clinic for 80 years! Recently it is also recognized that anti-epileptics of the classes of voltage-gated calcium channel (VGCC) blockers such as gabapentinoids, and of the

*Correspondence to: Keppel Hesselink JM, Department of health, University of Witten/Herdecke, Germany; Institute for Neuropathic Pain, Bosch en Duin, the Netherlands, E-mail: jan@neuropathie.nu

Received: July 19, 2018; Accepted: July 28, 2018; Published: July 31, 2018
Voltage-gated sodium channel (VGSC) blockers such as phenytoin, also might have their use in inflammatory pain conditions. The density and distribution as well as the expression of both types of channels influence afferent fiber excitability, not only in neuropathic pain states, but also in inflammatory pain states [8,9]. New approaches try to target both. For instance, one can suppress inflammatory and neuropathic pain quickly after a peripheral block of hyperpolarisation-activated cyclic nucleotide-gated ion channels by a compound as ivabradine [7]. Interestingly phenytoin has been document to possess clear anti-inflammatory characteristics too [10-11]. Furthermore, phenytoin also has neuroprotective properties, and these might be for a part dependent of its anti-inflammatory mode of action, Figure 1 [12-13].

**Administrating topical phenytoin cream in peripheral neuropathic pain**

The administration of a topical phenytoin formulation on the skin suffering from painful SFN is therefore a logical step. We recently developed a cream, containing a range of 5%-20% of phenytoin [14]. The choice of phenytoin is further supported by recent findings of elevated local proinflammatory cytokines in length-dependent small fiber neuropathy [15]. Another symptom, regularly present in patients suffering from SFN, such as muscle cramps is also possibly related to a local mediators of inflammation released by damaged small nerve that excite intramuscular nerve [16].

From 2015 onwards we have gathered information on the treatment of peripheral painful neuropathies with a special developed topical phenytoin-formulation. We have pointed out that especially such topical formulation based on the broad acting sodium channel blocker phenytoin is more fit to induce sufficient analgesia that topical phenytoin-formulation. We have pointed out that especially such topical formulation based on the broad acting sodium channel blocker phenytoin is more fit to induce sufficient analgesia that topical phenytoin-formulation.

We also concluded that there is a dose-effect relationship; the analgesic effects of 10% phenytoin cream lasts around twice as long as cream containing 5% phenytoin [19].

Navigating the sodium channels, in case of peripheral neuropathic pain, where the pathogenesis is residing in small fibers and nociceptors, is possible with phenytoin cream. This is therefore a new and interesting treatment option. We are currently at the start of a phase III program, after consultation with the Dutch Medicines Evaluation Board [20].

**Conflict of interest**

The author is a patent holder of two patents related to the topical formulations of phenytoin in the treatment of neuropathic pain.

**References**

10. Young GT, Emery EC, Mooney ER, Tsantoulas C, McNaughton PA (2014) Inflammatory and neuropathic pain are rapidly suppressed by peripheral block of hyperpolarisation-activated cyclic nucleotide-gated ion channels. Pain 155: 1708-1719. [Crossref]